Media coverage about NxStage Medical (NASDAQ:NXTM) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NxStage Medical earned a news impact score of 0.08 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 47.0041525889663 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
NxStage Medical (NASDAQ:NXTM) traded up 0.11% during trading on Monday, reaching $27.82. The company’s stock had a trading volume of 19,841 shares. The stock’s market cap is $1.84 billion. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80. The firm has a 50 day moving average price of $27.58 and a 200-day moving average price of $25.90.
NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). The firm had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.03) earnings per share. On average, analysts expect that NxStage Medical will post ($0.05) earnings per share for the current year.
Several brokerages have recently commented on NXTM. Jefferies Group LLC cut NxStage Medical from a “buy” rating to a “hold” rating and decreased their target price for the stock from $33.00 to $30.00 in a report on Tuesday, August 8th. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a report on Thursday, August 10th. BTIG Research cut NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. Northland Securities reiterated a “hold” rating and issued a $30.00 price target on shares of NxStage Medical in a report on Monday, August 7th. Finally, Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target on the stock. in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. The company has an average rating of “Hold” and a consensus target price of $30.25.
COPYRIGHT VIOLATION WARNING: This report was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/09/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-nxstage-medical-nxtm-share-price.html.
In related news, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $25.19, for a total value of $25,190.00. Following the sale, the president now directly owns 75,903 shares of the company’s stock, valued at $1,911,996.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $23.29, for a total value of $100,147.00. Following the completion of the sale, the senior vice president now directly owns 29,637 shares in the company, valued at $690,245.73. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,400 shares of company stock worth $1,386,536. Company insiders own 4.70% of the company’s stock.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.